×
Dynavax Technologies Receivables 2010-2025 | DVAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Dynavax Technologies receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
View More
Dynavax Technologies Receivables 2010-2025 | DVAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Dynavax Technologies receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$247.8B
Amgen (AMGN)
$154.9B
Gilead Sciences (GILD)
$140.2B
Vertex Pharmaceuticals (VRTX)
$100.3B
Bristol Myers Squibb (BMY)
$96B
GSK (GSK)
$80.8B
CSL (CSLLY)
$67.1B
Regeneron Pharmaceuticals (REGN)
$61.5B
Alnylam Pharmaceuticals (ALNY)
$58.5B
Argenex SE (ARGX)
$43.6B
Insmed (INSM)
$28.8B
BioNTech SE (BNTX)
$24B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$19.4B
Incyte (INCY)
$16.5B
Genmab (GNMSF)
$16.5B
Genmab (GMAB)
$16B
Illumina (ILMN)
$15.4B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11.2B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
QIAGEN (QGEN)
$10.3B
Exelixis (EXEL)
$10.1B
Moderna (MRNA)
$9.4B
Verona Pharma American Depositary Share (VRNA)
$9.2B
Exact Sciences (EXAS)
$9B
Bio-Techne Corp (TECH)
$8.6B
Halozyme Therapeutics (HALO)
$8.6B
Guardant Health (GH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B